The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,747.50
Bid: 1,747.00
Ask: 1,747.50
Change: 14.00 (0.81%)
Spread: 0.50 (0.029%)
Open: 1,736.00
High: 1,750.00
Low: 1,736.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London close: Stocks end flat after BoE and ECB decisions

Thu, 04th Oct 2012 17:02

- BoE and ECB hold rates- US data beats estimates- Next leads risers after broker commentsThe Footsie swung between gains and losses for most of Thursday's session but finished the day broadly flat following a busy day on the global economic calendar, which saw policy decisions in the UK and Europe, a news conference with Mario Draghi and some better-than-expected economic figures from the US.At midday, the Bank of England's Monetary Policy Committee (MPC) maintained the Bank Rate at 0.5% and the asset purchase programme at £375bn. The decision was more or less as expected, though many analysts are expecting the Bank to embark on further easing and possibly a rate cut in November.The European Central Bank (ECB) also remained in 'wait-and-see' mode this afternoon, leaving its key interest rate at 0.75% after it was cut by 25 basis points earlier in the year. In the following press meeting with ECB President Draghi, he said the "euro is irreversible" and explained that last month's decision to announce a bond-buying programme will act as an effective backstop for the Eurozone.Analyst Craig Erlam from Alpari said this afternoon: "It's very difficult to argue with this point, all you have to do is look at the borrowing costs of the peripheral countries to see that investors are much more comfortable with the situation in the Eurozone than they were a few months ago." Stateside, initial weekly jobless claims increased to 367,000 last week, more than the 363,000 recorded the week before but under the 370,000 expected by the consensus. Factory orders fell by 5.2% in August, the second fall in three months, according to the Commerce Department. This was better than the 5.9% decline forecasted.In Eurozone news, Spain's Treasury sold €3.99bn in two-, three- and five-year debt, the top end of its targeted range. While bid-to-cover ratios improved across all maturities, the yields on offer fell. Meanwhile, the Troika has said it expects the Greek economy to contract by 5% in 2013, notably worse than the 3.8% fall in gross domestic product (GDP) expected by Greece's own government. FTSE 100: Retailers mixed; Tesco continues to fallSupermarket groups Tesco and Sainsbury were stuck in the red today after announcing interim results and a trading update (respectively) yesterday. Both Exane BNP Paribas and Credit Suisse reduced their target prices for Tesco's shares today.Retailing peers Next, Kingfisher and Marks & Spencer were heading the other day, with Next topping the risers list on the Footsie after an upbeat broker note from Nomura. The broker said that cotton prices should start to benefit clothing retailers: "We believe retailers will start to benefit from lower input costs over the next few quarters, from a lagged benefit from the fall in cotton prices, and also increasing productivity levels in Chinese factories."BHP Billiton is among the companies talking to Petrobras about buying a stake in its Gulf of Mexico oilfields. The miner was trading in the red today after analysts at Morgan Stanley lowered their price target for the shares from 2,180p to 2,100p. Pharmaceuticals behemoth GlaxoSmithKline gained after saying its joint venture company, Shionogi-ViiV Healthcare, has completed an initial clinical registration package for dolutegravir, its treatment for HIV patients. Sweeteners and food products group Tate & Lyle was the high riser after Credit Suisse raised its rating for the stock from 'neutral' to 'outperform'. The broker said: "There is no easy way to value Tate & Lyle, but it does seem to us to be a better business for all the changes we have seen and that this is not reflected in the share price (which is down 8% year to date versus a staples sector up 18%)." FTSE 250: Halfords accelerates after impressive Q2Car and bike parts retailer Halfords jumped after appointing a new Chief Executive Officer following the abrupt departure of David Wild in the summer, as it revealed that full-year profits would be at the top end of guidance after a strong second quarter. The company expects pre-tax profit to be in the region of £40-42m in the first half on the back of its second quarter performance and an acceleration of operating cost investment. The consensus estimate prior to the announcement stood at £35.8m. Both Panmure Gordon and Seymour Pierce raised their target prices for the shares today. Transport company FirstGroup was firmer following the 20.7% drop the day before after the Department for Transport cancelled the decision to award the group the West Coast rail franchise. UBS this morning has upgraded the stock from 'sell' to 'neutral' after yesterday's big fall, but said that there are still "major challenges ahead". Morgan Stanley also raised its rating to 'equal weight', while HSBC downgraded to 'underweight'. FTSE 100 - RisersNext (NXT) 3,592.00p +2.66%Weir Group (WEIR) 1,800.00p +2.16%Tate & Lyle (TATE) 687.00p +1.85%InterContinental Hotels Group (IHG) 1,669.00p +1.83%Pearson (PSON) 1,252.00p +1.79%Tullow Oil (TLW) 1,420.00p +1.72%Aggreko (AGK) 2,347.00p +1.65%Carnival (CCL) 2,350.00p +1.60%Kingfisher (KGF) 268.70p +1.59%Smiths Group (SMIN) 1,055.00p +1.54%FTSE 100 - FallersTesco (TSCO) 318.15p -2.99%Xstrata (XTA) 948.30p -2.08%Johnson Matthey (JMAT) 2,369.00p -1.99%Lloyds Banking Group (LLOY) 38.02p -1.98%BHP Billiton (BLT) 1,912.50p -1.57%Morrison (Wm) Supermarkets (MRW) 280.40p -1.54%G4S (GFS) 264.30p -1.38%Croda International (CRDA) 2,380.00p -1.20%CRH (CRH) 1,175.00p -1.18%Royal Dutch Shell 'B' (RDSB) 2,200.00p -1.10%FTSE 250 - RisersHalfords Group (HFD) 303.50p +14.10%Sports Direct International (SPD) 382.80p +6.33%Bwin.party Digital Entertainment (BPTY) 116.10p +6.22%Rentokil Initial (RTO) 87.25p +5.12%New World Resources A Shares (NWR) 276.00p +3.72%FirstGroup (FGP) 200.60p +3.72%Victrex (VCT) 1,380.00p +3.68%Imagination Technologies Group (IMG) 496.20p +3.59%Workspace Group (WKP) 281.90p +3.37%PayPoint (PAY) 765.00p +3.24%FTSE 250 - FallersPetra Diamonds Ltd.(DI) (PDL) 113.40p -2.49%Heritage Oil (HOIL) 186.90p -2.10%IP Group (IPO) 118.50p -1.66%NMC Health (NMC) 191.50p -1.64%Afren (AFR) 139.50p -1.62%Bovis Homes Group (BVS) 493.90p -1.32%Euromoney Institutional Investor (ERM) 774.50p -1.27%Kenmare Resources (KMR) 39.70p -1.12%Essar Energy (ESSR) 118.00p -1.09%Tullett Prebon (TLPR) 293.90p -1.08%BC
More News
3 Apr 2024 22:01

Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs

WASHINGTON, April 3 (Reuters) - President Joe Biden hosted a White House event with U.S. Senator Bernie Sanders on Wednesday to tout their fight against high prescription drug prices and push companies to cut the cost of inhalers for asthma sufferers.

Read more
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.